Skip to main content
. Author manuscript; available in PMC: 2020 May 28.
Published in final edited form as: J Control Release. 2019 Apr 8;302:181–189. doi: 10.1016/j.jconrel.2019.04.009

Fig. 4. Log inhibition curves (IC50) of C3 opsonization and C5a release in plasma by clinically approved nanomedicines.

Fig. 4

A) Nanoparticles used were Feraheme, LipoDox and Onivyde. Nanoparticles were incubated in plasma in the presence or absence of increasing concentration of SCR-2-3-4 as described in Methods. B) C3 deposition, Feraheme; B) C5a levels, Feraheme; C) C3 deposition, LipoDox; D) C5a levels, LipoDox; E) C3 deposition, Onivyde; F) C5a levels, Onivyde. Each graph shows a corresponding IC50 value above. Representative inhibition curve is shown for one donor; multiple donors are compiled in Table 2. All graphs show raw values on Y-axis. Each point is the average of 3 technical replicates.